Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703908 · ClinicalTrials.gov registry record · Phase 2
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03703908: Clinical Trial Phase 2 study, sponsored by Amgen.
NCT03703908 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03703908, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
Primary Outcome
Number of subjects with a reduction in Urine Protein to Creatinine Ratio (UPCR) of at least 20% , i.e., ≥20%, by Week 12.
Interventions
- DRUG CCX140-B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2020-06-24 |
| Phase | Phase 2 |
Why NCT03703908 stopped before completion
NCT03703908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which CCX140-B is the first listed.
NCT03703908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03703908 about?
NCT03703908 is a clinical study titled "A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome". An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
What is the current status of trial NCT03703908?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-10-01. Estimated completion is 2020-06-24.
What interventions are being tested in trial NCT03703908?
The interventions under investigation include: CCX140-B (DRUG).
Who is sponsoring clinical trial NCT03703908?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03703908's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI